Dr Ian Reynolds and colleagues used meta-analytical techniques to compare the clinicopathological characteristics and survival outcomes of inflammatory bowel disease (IBD) associated and sporadic colorectal carcinoma.
Patients with IBD have an established increased risk of developing colorectal cancer.
There is no consensus, however, on the clinicopathological characteristics, and survival outcomes of IBD associated colorectal cancer when compared to sporadic colorectal cancer.
|IBD associated colorectal cancer had an increased rate of synchronous tumors|
|International Journal of Colorectal Diseases|
The team performed a comprehensive search for published studies comparing IBD associated and sporadic colorectal cancer.
Data were retrieved from 20 studies describing 571,278 patients.
The team found that IBD associated colorectal cancer had an increased rate of synchronous tumors, poor differentiation, and a reduced rate of rectal cancer.
IBD associated colorectal cancer, however, did not affect the frequency of T3/T4 tumors, lymph node positivity, metastasis at presentation, sex distribution, or 5-year overall survival.
Dr Reynolds' team comments, "In this large analysis of available data, IBD associated colorectal cancer was characterized by less rectal tumors and more synchronous and poorly differentiated tumors compared with sporadic cancers, but no discernable difference in sex distribution, stage at presentation, or survival could be identified."